Could bacteria or viruses be rendered harmless by tomatoes or its products? Researchers investigated if tomato substances work against S. typhi.
Is an earlier onset of puberty and hormone fluctuations associated with an increased cardiometabolic risk in adulthood?
The link between childhood amblyopia and later cardiometabolic dysfunction has been known for some time But how high is amblyopia's risk?
The air you breathe in aircrafts is routinely contaminated by small amounts of engine oils and hydraulic fluids. Could these pollutants be harmful?
During the ESMO Congress on Gynaecological Cancers, Prof. Scambia analysed developments in the field, and what's next in the coming decade.
Precision medicine is revolutionising treatments for colon cancer and other gastrointestinal malignancies by identifying biomarkers for personalised therapies.
New immunotherapies go beyond CTLA-4 and PD(L)1 and show promising results for treating various types of cancer, including colorectal cancer.
Summer season is coming, and with it, time by the pool; but also possibly some more cases of “Margarita burn” or phytophotodermatitis.
In a first, haemodiafiltration was shown to have a lower risk of death than haemodialysis. Results could change current dialysis practice.
The combination was associated with deep and durable responses in previously untreated high-risk CLL, SLL, and del(17p) and/or TP53 mutations.
High-risk participants with heavily pre-treated relapsed or refractory follicular lymphoma benefitted in clinical remission and survival outcomes.
In a heavily pretreated population of participants with KMT2A rearranged acute leukaemia, revumenib displayed encouraging anti-tumour activity.
Sovleplenib was associated with early and durable platelet responses in participants with primary immune thrombocytopenia.
Harmful environmental influences, such as air and noise pollution or light pollution at night, can also contribute to susceptibility to disease.
Renizgamglogene autogedtemcel (reni-cel) established a swift and durable normalisation in haemoglobin and improvements in haemolysis markers.
Asciminib was superior to all other tested first-line tyrosine kinase inhibitors (TKIs) in participants with chronic myeloid leukaemia (CML).
Epcoritamab delivered encouraging efficacy data and a favourable safety profile in participants with high-risk Richter’s transformation (RT).
Mitapivat improved Hb levels and fatigue in participants with non-transfusion-dependent alpha or beta thalassaemia (NTDT) in a phase 3 study.
Treatment with pelabresib plus ruxolitinib was associated with improvements in all 4 hallmarks of myelofibrosis, the phase 3 MANIFEST-2 trial showed.
JAK inhibitor-naïve participants with myelofibrosis benefitted from a regimen of navitoclax plus ruxolitinib compared with ruxolitinib and a placebo.